Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

Details 詳細情報について

• CRID

  1361418519673445504

• DOI

  10.1016/s1470-2045(14)70461-9

• ISSN

  14702045

• Web Site

  https://api.elsevier.com/content/article/PII:S1470204514704619?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S1470204514704619?httpAccept=text/plain

• Data Source

  • Crossref